Literature DB >> 27198212

Detection of Leishmania donovani in peripheral blood of asymptomatic individuals in contact with patients with visceral leishmaniasis.

Sultana S Banu1, Wieland Meyer2, Be-Nazir Ahmed3, Rady Kim4, Rogan Lee5.   

Abstract

BACKGROUND: The majority of individuals infected with Leishmania donovani complex remain asymptomatic. They may act as transmission reservoirs for visceral leishmaniasis (VL). We investigated sero-prevalence of L. donovani complex amongst those closely associated with patients with VL and whether these sero-reactive individuals had Leishmania parasites in their peripheral blood. Other risk factors were also investigated.
METHODS: A total of 257 individuals in contact with patients with VL were tested for anti-Leishmania antibodies by rK39 immunochromatographic test (rK39 ICT), ELISA using promastigote antigen (p-ELISA) and indirect fluorescent antibody test (IFAT). Buffy coats of rK39 ICT positive individuals were cultured; sero-reactive buffy coats were tested for Leishmania DNA by ITS1 PCR. DNA obtained from culture was sequenced to confirm Leishmania species. Risk factors were evaluated for each sero-positive sample.
RESULTS: The results showed 29.2% (75/257) prevalence by serological tests: 14.4% (37/257) were positive by rK39 ICT, 25.3% (65/257) by p-ELISA, 18.3% (47/257) by IFAT and 10.9% (28/257) by all three serological methods. Ten percent (3/30) of cultures were positive for Leishmania promastigotes. Only 3% (2/74) sero-reactive buffy coats were positive for DNA; sequence analysis revealed L. donovani species. Significant risk factors were age, working as farmers, domestic animals in household and proximity to animal shelters.
CONCLUSIONS: Asymptomatic family members of patients with VL can carry live L. donovani in peripheral blood and may act as potential reservoirs. GENBANK ACCESSION NUMBER: BankIt1863680 Leishmania KT921417 (DNA sequences of the ribosomal ITS1 region of L. donovani).
© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Asymptomatic infection; Bangladesh; Culture; Leishmania; PCR; Serology

Mesh:

Substances:

Year:  2016        PMID: 27198212      PMCID: PMC4914877          DOI: 10.1093/trstmh/trw027

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  34 in total

1.  Leishmania donovani in blood smears of asymptomatic persons.

Authors:  M C Sharma; A K Gupta; V N Das; N Verma; N Kumar; R Saran; S K Kar
Journal:  Acta Trop       Date:  2000-09-18       Impact factor: 3.112

2.  Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors.

Authors:  Karl Schenkel; Suman Rijal; Siddhartha Koirala; Shekhar Koirala; Veerle Vanlerberghe; Patrick Van der Stuyft; Marina Gramiccia; Marleen Boelaert
Journal:  Trop Med Int Health       Date:  2006-12       Impact factor: 2.622

3.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

4.  Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India.

Authors:  Roshan K Topno; Vidya N R Das; Alok Ranjan; Krishna Pandey; Dharmender Singh; Nawin Kumar; Niyamat A Siddiqui; Vijay P Singh; Shreekant Kesari; Narendra Kumar; Sanjeev Bimal; Annadurai Jeya Kumar; Chetram Meena; Ranjeet Kumar; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

5.  Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen.

Authors:  Sarman Singh; Veena Kumari; Niti Singh
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 6.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

7.  Epidemiology of visceral leishmaniasis in northeast Brazil.

Authors:  T G Evans; M J Teixeira; I T McAuliffe; I Vasconcelos; A W Vasconcelos; A de A Sousa; J W Lima; R D Pearson
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

8.  Risk factors for kala-azar in Bangladesh.

Authors:  Caryn Bern; Allen W Hightower; Rajib Chowdhury; Mustakim Ali; Josef Amann; Yukiko Wagatsuma; Rashidul Haque; Katie Kurkjian; Louise E Vaz; Moarrita Begum; Tangin Akter; Catherine B Cetre-Sossah; Indu B Ahluwalia; Ellen Dotson; W Evan Secor; Robert F Breiman; James H Maguire
Journal:  Emerg Infect Dis       Date:  2005-05       Impact factor: 6.883

9.  How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data.

Authors:  Rajib Chowdhury; Dinesh Mondal; Vashkar Chowdhury; Shyla Faria; Jorge Alvar; Shah Golam Nabi; Marleen Boelaert; Aditya Prasad Dash
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

10.  Low prevalence of Leishmania donovani infection among the blood donors in kala-azar endemic areas of Bangladesh.

Authors:  M Mamun Huda; Shikha Rudra; Debashis Ghosh; Khondaker Rifat Hasan Bhaskar; Rajib Chowdhury; Aditya Prasad Dash; Sujit Kumar Bhattacharya; Rashidul Haque; Dinesh Mondal
Journal:  BMC Infect Dis       Date:  2013-02-02       Impact factor: 3.090

View more
  8 in total

1.  Human Competence to Transmit Leishmania infantum to Lutzomyia longipalpis and the Influence of Human Immunodeficiency Virus Infection.

Authors:  Gabriel Reis Ferreira; José Carlos Castelo Branco Ribeiro; Antônio Meneses Filho; Teresinha de Jesus Cardoso Farias Pereira; Daniela Moura Parente; Humberto Feitosa Pereira; Jailthon Carlos da Silva; Danielle Alves Zacarias; Letiano Vieira da Silva; Symonara Karina Medeiros Faustino; Walfrido Salmito Almeida Neto; Dorcas Lamounier Costa; Ivete Lopes de Mendonça; Carlos Henrique Nery Costa
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

2.  Immunization with Live Attenuated Leishmania donovani Centrin-/- Parasites Is Efficacious in Asymptomatic Infection.

Authors:  Nevien Ismail; Amit Kaul; Parna Bhattacharya; Sreenivas Gannavaram; Hira L Nakhasi
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

3.  Evaluation of recombinant K39 antigen and various promastigote antigens in sero-diagnosis of visceral leishmaniasis in Bangladesh.

Authors:  Sultana Shahana Banu; Be-Nazir Ahmed; Abul Khair Mohammad Shamsuzzaman; Rogan Lee
Journal:  Parasite Epidemiol Control       Date:  2016-07-30

4.  Systematic review on antigens for serodiagnosis of visceral leishmaniasis, with a focus on East Africa.

Authors:  Vera Kühne; Zahra Rezaei; Paul Pitzinger; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2019-08-15

5.  Seroprevalence of Asymptomatic Leishmania donovani among Laborers and Associated Risk Factors in Agricultural Camps of West Armachiho District, Northwest Ethiopia: A Cross-Sectional Study.

Authors:  Animen Ayehu; Yibeltal Aschale; Wossenseged Lemma; Animut Alebel; Ligabaw Worku; Ayalew Jejaw; Abebe Genetu Bayih
Journal:  J Parasitol Res       Date:  2018-11-28

Review 6.  Identification of asymptomatic Leishmania infections: a scoping review.

Authors:  Ana Victoria Ibarra-Meneses; Audrey Corbeil; Victoria Wagner; Chukwuemeka Onwuchekwa; Christopher Fernandez-Prada
Journal:  Parasit Vectors       Date:  2022-01-05       Impact factor: 3.876

7.  Optimization of loop-mediated isothermal amplification (LAMP) assays for the detection of Leishmania DNA in human blood samples.

Authors:  Ibrahim Abbasi; Oscar D Kirstein; Asrat Hailu; Alon Warburg
Journal:  Acta Trop       Date:  2016-06-08       Impact factor: 3.112

8.  Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients.

Authors:  Wen-Wei Zhang; Ayan Kumar Ghosh; Raodoh Mohamath; Jacqueline Whittle; Alessandro Picone; Patrick Lypaczewski; Momar Ndao; Randall F Howard; Pradeep Das; Steven G Reed; Greg Matlashewski
Journal:  BMC Infect Dis       Date:  2018-10-03       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.